Navigation Links
Takeda presenta la richiesta di autorizzazione all'immissione in commercio nell'Unione Europea per Vedolizumab nella colite ulcerosa moderata-grave e nella malattia di Crohn
Date:3/8/2013

ltri termini e frasi simili, nonché da espressioni che, al contrario, li neghino. Le dichiarazioni previsionali si basano su stime e ipotesi formulate dal management e da quest'ultimo ritenute ragionevoli, benché siano intrinsecamente incerte e difficilmente prevedibili. Gli investitori sono invitati a non fare eccessivo affidamento su tali dichiarazioni previsionali.

Le dichiarazioni previsionali implicano rischi e incertezze che potrebbero esplicitarsi in conseguenze reali o esperienze sostanzialmente diverse da quanto in esse espresso o da esse implicitamente desumibile. Tali rischi e incertezze includono, a puro titolo esemplificativo, (1) circostanze economiche che possano influenzare le attività di Takeda , tra cui le condizioni economiche generali in Giappone, Stati Uniti e resto del mondo, (2) pressioni provenienti da competitori e sviluppi da parte della concorrenza, (3) leggi e normative applicabili, (4) successo o fallimento dei programmi di sviluppo del prodotto, (5) azioni condotte delle autorità  regolatorie e tempistica correlata, (6) variazioni dei tassi di cambio, (7) rivendicazioni o preoccupazioni relative alla sicurezza o all'efficacia di prodotti commercializzati, ovvero di prodotti candidati alla fase di sviluppo e, infine, (8) attività d'integrazione con società acquisite.

Le dichiarazioni previsionali contenute in questo comunicato stampa sono valide solo alla data del presente comunicato stampa. Takeda non assume alcun obbligo di rivedere o aggiornare alcuna dichiarazione previsionale in base a nuove informazioni, o a eventi o circostanze future, successive alla data di pubblicazione della presente dichiarazione previsionale. Se Takeda aggiorna o corregge una o più delle presenti dichiarazioni, gli investitori e gli altri soggetti interessati non dovranno da ciò desumerne ulteriori aggiornamenti o correzioni in futuro da parte
'/>"/>

SOURCE Takeda Pharmaceutical Company Limited
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Takeda Submits Marketing Authorisation Application for Vedolizumab in Moderately to Severely Active Ulcerative Colitis and Crohns Disease in the European Union
2. Takeda and Resolve Therapeutics Enter Autoimmune Partnership
3. Takeda Receives FDA Approval for Three New Type 2 Diabetes Therapies, NESINA (alogliptin) and Fixed-Dose Combinations OSENI (alogliptin and pioglitazone) and KAZANO (alogliptin and metformin HCl)
4. FDA Accepts Takeda and Lundbecks Submission of the New Drug Application for Vortioxetine for the Treatment of Major Depressive Disorder
5. Takedas Deerfield Campus Ranked Among Chicagos Top 100 Workplaces in 2012
6. Takeda Completes its Russian Pharmaceutical Manufacturing Facility
7. Takeda Resubmits New Drug Applications to the United States Food and Drug Administration for Alogliptin and the Fixed-Dose Combination Alogliptin and Pioglitazone
8. Zacks Bull and Bear of the Day Highlights: Discover Financial Services, POSCO, AstraZeneca, Bayer and Takeda Pharmaceutical
9. Takeda to Acquire Multilab, Enhancing its Business Infrastructure in Brazil
10. Cellular Dynamics Announces Presentations at the Society of Toxicologys 52nd Annual Meeting Demonstrating the Expanding Impact of iPSC-Derived Human Cells on Toxicology Assay Development
11. Boston Scientific Updates PREVAIL Late Breaking Clinical Trials Presentation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... 17, 2014 The ambulance equipment ... decade due to the recession, an unstable ... advancements. This BCC Research report analyzes present ... the ambulance and emergency medical services equipment ... hemorrhage control devices, equipment used for burn ...
(Date:9/17/2014)... , Sept. 17, 2014  Dr. Stephen ... the White House today for National Recovery Month, stars ... consumer advocates released today. Consumer advocates were also joined ... who spoke out after losing her fiancée because of ... the doctor had a history of crack cocaine abuse. ...
(Date:9/17/2014)... Sept. 17, 2014 /PRNewswire-iReach/ -- ChemImage announced ... discussing improvements in the development of imaging ... both normal and diseased tissue that minimizes ... surgical procedures, lowers surgical costs and potentially ... The clinical and scientific ...
Breaking Medicine Technology:Ambulance and Emergency Equipment: Global Markets 2Ambulance and Emergency Equipment: Global Markets 3Ambulance and Emergency Equipment: Global Markets 4Doctor Recovering From 100-Pill-A-Day Addiction Stars In New Ad Supporting Prop 46; Appears At White House for National Recovery Month, Says Consumer Watchdog Campaign 2Doctor Recovering From 100-Pill-A-Day Addiction Stars In New Ad Supporting Prop 46; Appears At White House for National Recovery Month, Says Consumer Watchdog Campaign 3Patient Outcomes Improve When Molecular Chemical Imaging Technology Is Used to Aid Robotic Surgical Procedures, According to New White Paper 2
... 4 Novartis Vaccines & Diagnostics Inc. and Novartis ... to resolve civil False Claims Act allegations arising from the ... announced today. The settlement resolves allegations that, between Jan. ... and its predecessor, Chiron Corporation, caused false claims to be ...
... Joseph F. Finn, Jr. , C.P.A. ("Finn"),  Assignee for ... that the MRI imaging intellectual properties of the EP-3600 MRI imaging ... assets of Epix were transferred to him on July 20, ... Epix creditors.  He recently reached an agreement with Bayer Schering Pharma ...
Cached Medicine Technology:Novartis Vaccines & Diagnostics to Pay More Than $72 Million to Resolve False Claims Act Allegations Concerning TOBI 2Novartis Vaccines & Diagnostics to Pay More Than $72 Million to Resolve False Claims Act Allegations Concerning TOBI 3Epix Pharmaceuticals, Inc. Announces the May 28, 2010 Auction Sale of EP-3600 MRI Imaging Agent 2
(Date:9/17/2014)... Dallas, TX (PRWEB) September 17, 2014 ... they were recently granted several awards for their top-notch ... regarding patient experience, orthopedic care and GYN surgery. , ... Patient Safety Excellence Award™. They have received this award ... ranked among the top 5 percent in the nation ...
(Date:9/17/2014)... News, VA (PRWEB) September 17, 2014 ... will host recruit757’s scholarship workshop for football players ... on Tuesday, Sept. 23. , Doors open at 6:30 ... Performance Center and speak to trainers and physical therapists. ... until 9 p.m. , The Newport News Tidewater Performance ...
(Date:9/17/2014)... messages about the health benefits of quitting smoking may ... suggests. Although smokers who think quitting will be ... effects of smoking, researchers found smokers who believe they ... or positive, messages about how quitting will improve their ... of both types of messages might get more people ...
(Date:9/17/2014)... September 17, 2014 Prevention is the ... is hospitalizing scores of infants, children and teenagers in ... Kirk Mahon, medical director of Legacy ER & Urgent ... been no reported cases of EV-D68 so far in ... that could change,” he said. “Implementing prevention strategies now ...
(Date:9/17/2014)... 17, 2014 Boston Children’s Museum ... a monthly concert series, introducing young Museum visitors ... Top, America’s premier national platform celebrating the stories, ... of the young musicians featured will also be ... Children’s Museum is fortunate to partner with the ...
Breaking Medicine News(10 mins):Health News:North Central Surgical Center Receives Several Accolades 2Health News:Tidewater Physical Therapy and Performance Services and recruit757 To Host Football Scholarship Seminar 2Health News:Tidewater Physical Therapy and Performance Services and recruit757 To Host Football Scholarship Seminar 3Health News:More Than One Kind of Message May Convince Smokers to Quit, Study Says 2Health News:Legacy ER & Urgent Care Warns North Texans about Dangers of Enterovirus D68 2Health News:Boston Children's Museum Partners with From the Top to Offer Monthly Concert Series 2Health News:Boston Children's Museum Partners with From the Top to Offer Monthly Concert Series 3
... News) -- Body-building and weight-loss products are the types of ... a small new study. Liver injury from medication is ... and herbal supplements -- which do not require a prescription ... are used by up to 40 percent of people in ...
... (ICUs) that have no or limited access to critical care ... the specialists, called intensivists, staff the unit at night, according ... Pittsburgh School of Medicine and UPMC. However, the researchers were ... ICUs that were robustly staffed with the specialists during the ...
... Va. (May 22, 2012) The Food and Drug Administration ... group of rare cell disorders. The test, or assay, was ... field of mast cells. Lawrence Schwartz, M.D., Ph.D., chair ... Charles and Evelyn Thomas Professor of Medicine at VCU, has ...
... , TUESDAY, May 22 (HealthDay News) -- Got hair? If ... cancer, a preliminary study suggests. Researchers are reporting ... more likely to have cancer than were those with more ... that they may benefit from being screened earlier and perhaps, ...
... are not effective in determining which asthma patients are ... (ICS) medications without risk of flare-ups or exacerbations, according ... United Kingdom. The study also showed that nearly three-quarters ... use of ICS medications once their symptoms are under ...
... The new blood thinner Xarelto appears to lower the chances ... U.S. Food and Drug Administration review has found. The ... advance of an FDA advisory panel meeting Wednesday, at which ... of Xarelto for treating people with acute coronary syndrome (a ...
Cached Medicine News:Health News:Body Building, Diet Supplements Linked to Liver Damage: Study 2Health News:Intensivists at night improve patient outcomes in some ICUs, says Pitt/UPMC team 2Health News:FDA clears test developed in partnership with VCU researcher 2Health News:Do Bald Men Face Higher Risk of Prostate Cancer? 2Health News:Do Bald Men Face Higher Risk of Prostate Cancer? 3Health News:Identifying asthma patients who tolerate lower doses of steroids remains problematic 2Health News:Identifying asthma patients who tolerate lower doses of steroids remains problematic 3Health News:New Blood Thinner May Lower Chances of Clots in High-Risk Heart Patients: FDA 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: